Maximizing Options to Advance Informed Choice for HIV Prevention (MOSAIC) is a seven-year (2021–28) global project funded by PEPFAR through USAID to help adolescent girls and young women and other women prevent HIV by accelerating introduction and scale-up of new and emerging biomedical prevention products.
MOSAIC works across multiple countries to implement user-centered research and research translation efforts to identify, understand and remove barriers to new product introduction, access and use; coordinate and provide technical assistance to global, national and subnational stakeholders to expedite product launch and scale-up; and strengthen the capacity of a wide range of local partners to perform essential functions that support the introduction of HIV prevention products.
The MOSAIC consortium is led by FHI 360 along with core partners Wits RHI, Pangaea Zimbabwe, LVCT Health, Jhpiego and AVAC. Local partner leadership and engagement, particularly in East and Southern Africa, is intrinsic to the project’s approach to expediting women’s access to new HIV prevention products. The work is also supported by technical partners from Afton Bloom, Avenir Health, Columbia University, Mann Global Health, RTI International, the University of Pittsburgh and the University of Washington.
Working closely with product developers, MOSAIC advances access to and uptake within a multiproduct market that includes options such as oral pre-exposure prophylaxis (oral PrEP), the dapivirine ring (PrEP ring) and injectable long-acting cabotegravir (CAB PrEP). Priority countries for the consortium’s work are Botswana, Eswatini, Kenya, Lesotho, Namibia, Nigeria, South Africa, Uganda, Zambia and Zimbabwe.
Blog
Twitter
LinkedIn
MOSAIC resources
To help prevent HIV, young people must be meaningfully engaged
